Table 5. Multivariate-adjusted linear regression modelsa between eGFR and serum PUFAs, including EPA+DHA, in the Sasayama study, 2012–2013.
Independent variables | ||||
eGFRcre | eGFRcys | |||
Standardized coefficients |
P value | Standardized coefficients |
P value | |
Model 1 | ||||
Serum EPA+DHA | −0.012 | 0.815 | 0.097 | 0.025 |
Serum α-linolenic acid | 0.088 | 0.191 | 0.015 | 0.797 |
Serum AA | 0.008 | 0.862 | −0.025 | 0.541 |
Serum linoleic acid | −0.144 | 0.064 | −0.016 | 0.803 |
Model 2 | ||||
Serum EPA+DHA | 0.014 | 0.770 | 0.096 | 0.015 |
Serum n-6 PUFAb | −0.055 | 0.313 | −0.022 | 0.622 |
AA, arachidonic acid; DHA, docosahexaenoic acid; EPA, eicosapentaenoic acid; GFR, glomerular filtration rate; PUFA, polyunsaturated fatty acids.
aRelationships between presented fatty acids and eGFR were evaluated by linear regression model after adjusting for age, sex, BMI, presence of hypertension and diabetes mellitus, serum HDL- and LDL- cholesterol level, medication for dyslipidemia, current smoking and drinking, and log-transformed C-reactive protein.
bSerum n-6 PUFA: sum of linoleic acid, γ-linolenic acid, dihomo-γ-linolenic acid, and arachidonic acid.